Skip to content

Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia

Efficacy and Cost Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Locally Advanced Head and Neck Cancer to Prevent Aspiration Pneumonia. A Randomized Phase II-III Study

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01598402
Acronym
PANTAP
Enrollment
106
Registered
2012-05-15
Start date
2011-12-31
Completion date
2014-12-31
Last updated
2013-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

LAHNC, Locally Advanced Head and Neck Cancer

Brief summary

Patients with locally advanced head and neck cancer treated with chemo-radiotherapy have (during and shortly after this treatment) a high risk of developing pneumonia by aspiration. This pneumonia is often associated with a hospital admission and affects the quality of life. The purpose of the study, is to determine whether prophylactic antibiotics may decrease the development of pneumonia. Prophylactic antibiotics means that there are no signs of pneumonia are already

Detailed description

Concomitant chemoradiotherapy (CRT) is used in locally advanced head and neck cancer (LAHNC). It will be administered to patients for unresectable disease or for organ preservation as primary treatment. Furthermore, it can be used as postoperative treatment in case high risk recurrent disease is present. This treatment induces a high rate of acute toxicity, such as mucositis, dermatitis, dysphagia, anorexia, and pain. Swallowing dysfunction and aspiration are seen in a high proportion (30%-100%) of patients and with an immense impact on Quality of life (QoL). Around half of the patients will develop an aspiration pneumonia during or shortly after the treatment. Patients, who develop fever during concomitant chemoradiotherapy, are most of the time admitted in the hospital. In the differential diagnosis pneumonia is on the first place in all those patients. The standard diagnostic procedures consist of a chest X-ray and culture of the sputum and blood. Pneumonia can lead to mortality in this frail patient group. The treatment of patients treated with chemoradiotherapy who develop fever and have a definite or suspected pneumonia, is administration of antibiotics, most frequently intravenous amoxicillin/clavulanic acid. LAHNC patients who are smoking and/or with malnutrition are at the highest risk of getting a pneumonia during or after radiotherapy. Because smoking is one of the risk factors of developing head and neck cancer chronic obstructive pulmonary disease (COPD) is frequently present in this group. Also, COPD is a known risk factor for developing pneumonias. Aspiration is seen in all primary sites of head and neck cancer, sometimes it is seen more frequently in patients with cancer of the larynx and hypopharynx. No data of prophylactic administration of antibiotics are available in LAHNC patients. However, a Cochrane review was published to assess the effects of prophylactic antibiotic regimens for the prevention of respiratory tract infections(RTIs) and overall mortality in adults receiving intensive care.

Interventions

DRUGamoxicillin/clavulanic acid suspension

625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with LAHNC which will be treated with CRT as discussed by a multidisciplinary team (i.e. a head and neck surgeon, a medical oncologist, and a radiation oncologist). This can be CRT as primary treatment or postoperative CRT. * Written informed consent * Expected adequacy of follow-up

Exclusion criteria

* Patients with pneumonia within the last 14 days before start of CRT * Patients with other infections within the last 14 days within the last 14 days before start of CRT * Patients with use of maintenance antibiotics * Patients with antibiotic treatment within the last 14 days before start of CRT * Patients with an allergy on amoxicillin

Design outcomes

Primary

MeasureTime frameDescription
the number of definite pneumonia and/ or suspected pneumoniafrom day 1 of 1 CRT until 3,5 mnd after the last CRTDefinite pneumonia: Evidence of pneumonia on chest radiography or 3 or more of the following: Sustained fever (temperature\> 100 f \[38°C\]), Rales or rhonchi on chest auscultation Sputum Gram stain showing substantial leukocytes Sputum culture showing a respiratory pathogen Suspected pneumonia: At least 2 of the 4 following features are present, without evidence of pneumonia on chest radiography: Sustained fever (temperature\> 100 f \[38°C\]) Rales or rhonchi on chest auscultation Sputum Gram stain showing substantial leukocytes Sputum culture showing a respiratory pathogen

Secondary

MeasureTime frameDescription
Number and kind of positive blood culturesfrom day 1 of 1 CRT until 3,5 mnd after the last CRT
number of admissions to hospitalfrom day 1 of 1 CRT until 3,5 mnd after the last CRT
Number of days of admissionfrom day 1 of 1 CRT until 3,5 mnd after the last CRT
effects on Quality of LifeBaseline, Day 28 last day of CRT, 3,5 months after CRTto investigate the effects on QoL after prophylactic treatment with antibiotics Patients fill in the following questionnaires: QLQ-C30, EORTC H&N35, PSHHN, EQ-5D and the VAS, SF-36
effects on mucositis: grade and durationfrom day 1 of 1 CRT until 3,5 mnd after the last CRTMucositis grade according to CTCAE v.4.0 and duration
side effects of amoxicillin/clavulanic acidfrom day 1 of 1 CRT until 3,5 mnd after the last CRTside effects of amoxicillin/clavulanic acid
Effects on numbers and causative agents of infections at other sitesduring follow upnumbers and causative agents of infections at other sites during follow up (3.5 months after the end of CRT)
Effects on mortalityfrom day 1 of 1 CRT until 3,5 mnd after the last CRTMortality due to definite and/or suspected pneumonia

Countries

Netherlands

Contacts

Primary ContactC. van Herpen, Md
c.vanherpen@onco.umcn.nl+31 24 361 03 53
Backup ContactC. Driessen, drs
c.driessen@onco.umcn.nl+31 24 361 11 11

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026